# US 2024/0226204 A9 · Influenza virus defective interfering particles for use in the prophylactic or therapeutic treatment of coronaviridae infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0226204 A9
- Document ID: US20240226204A9
- Status: Published application
- Kind: A9
- Application number: 18/546,690
- Filed: 2022-02-18
- Published: 2024-07-11
- Earliest claimed: 2021-02-18
- Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.; Otto-Von-Guericke-Universitat Magdeburg; Helmholtz-Zentrum FüR Infektionsforschung GmbH
- Applicants: Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V.; Otto-von-Guericke-Universität Magdeburg; Helmholtz-Zentrum für Infektionsforschung GmbH
- Inventors: Sascha KUPKE; Udo REICHL; Marc Dominique HEIN; Dunja BRUDER; ulfert RAND
- Web page: https://patentgrep.com/patent/US20240226204A9

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61P 31/14: for RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16123: Virus like particles [VLP]
- C12N 2760/16132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/16133: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.

## Claims

### Claim 1

A method for prophylactic or therapeutic treatment of coronaviridae infection in an individual comprising administering the individual influenza virus interfering particles (DIPs).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the influenza virus defecting interfering particles are influenza A virus defective interfering particles.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the coronaviridae infection is from orthocoronavirinae.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the coronaviridae infection is from sarbecovirus virus or merbecovirus.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the individual is provided prophylactic or therapeutic treatment of severe acute respiratory syndrome related to coronavirus 2 (SARS-CoV-2) infection.

### Claim at position 6

-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1 wherein, after infection of the individual, the individual administered the individual influenza virus interfering particles (DIPs) demonstrates at least one of
i. a reduction in the total number of virus particles,
ii. a severe reduction in the faction of infectious virus produced, and
iii. a stronger induction of the innate immune response expressed by type I IFN expression is observable.

### Claim 14 (depends on 1)

The method of claim 1 wherein the individual is selected from the group consisting of human, cat, ferret, dog, and mink.

### Claim 15

A method of therapeutically or prophylactically treating viral infection with coronaviridae in an individual in need thereof comprising administering the individual an effective amount of influenza virus interfering particles (DIPs).

### Claim 16 (depends on 15)

The method of therapeutically or prophylactically treating viral infection with coronaviridae according to claim 15, wherein administration is by mucosal administration.

### Claim 17 (depends on 15)

The method of therapeutically or prophylactically treating viral infection with coronaviridae in an individual according to claim 15, wherein administration by intranasal administration.

### Claim 18 (depends on 15)

The method of therapeutically or prophylactically treating viral infection with coronaviridae in an individual according to claim 15 wherein the influenza interfering virus particles (DIPS) are derived from a defective interfering influenza A virus,
i) wherein the nucleic acid sequence of segment 1 of the influenza A virus comprises:
a. A sequence collected from SEQ ID No. 1 or SEQ ID No. 2; or
b. a nucleic acid sequence of at least 99% identity with SEQ ID No. 1 or SEQ ID No. 2; or ii) wherein the nucleic acid sequence comprises SEQ ID No. 3 containing the following substituents: C3T, G4A, G8A, A100G, G113A, G130A, G240A, A241G, C334T, C353T, C361T, C370A, T371G, T385C, A401T, G434A, C442T, A443G, C453T, A454G, A524G, T643G, G645T, A648G, A667G, G670A, A716G, C793T, G801T, A805G, G874T, A887T, C888T, G894A, G943A, A18G, C535T, compared to the wild type sequence of SEQ ID No. 4; or a nucleic sequence having greater than 99% identity with the sequence of SEQ ID No. 3.

### Claim 19 (depends on 18)

The method of therapeutically or prophylactically treating viral infection according to claim 18 wherein the step of administration provides the individual an effective amount of IAV DIPs.

### Claim 20 (depends on 15)

The method according to claim 15 wherein the individual is suspected of or is infected with coronaviridae, wherein the DIPs are administered within 12 hours from a time point of the individual being infected or being suspected of being infected with coronaviridae.

### Claim 21 (depends on 15)

The method according to claim 15 wherein the whereby administration of the DIP is effected within one to two weeks before potential exposure of the individual to the coronaviridae virus.

### Claim 22 (depends on 15)

The method according to claim 15 wherein the prophylactic or therapeutic treatment of the an individual is against SARS-CoV.

### Claim 23 (depends on 22)

The method according to claim 22 wherein the individual is administered therapeutic effective amounts of DIPs DI244 or DIP OP7.

### Claim 24 (depends on 18)

The method of therapeutically or prophylactically treating viral infection with coronaviridae in an individual according to claim 18, wherein the defective interfering influenza A virus is a virus, i) wherein the nucleic acid sequence of segment 1 of the influenza A virus comprises:
a. A sequence collected from SEQ ID No. 1 or SEQ ID No. 2; or
b. a nucleic acid sequence of at least 99% identity with SEQ ID No. 1 or SEQ ID No. 2; or
ii) wherein the nucleic acid sequence comprises SEQ ID No. 3 containing the following substituents: C3T, G4A, G8A, A100G, G113A, G130A, G240A, A241G, C334T, C353T, C361T, C370A, T371G, T385C, A401T, G434A, C442T, A443G, C453T, A454G, A524G, T643G, G645T, A648G, A667G, G670A, A716G, C793T, G801T, A805G, G874T, A887T, C888T, G894A, G943A, A18G, C535T, compared to the wild type sequence of SEQ ID No. 4; or a nucleic sequence having greater than 99% identity with the sequence of SEQ ID No. 3, or
wherein the nucleic acid sequence comprises SEQ ID No. 3 or has greater than 99% identity with the sequence of SEQ ID No. 3.

### Claim 25 (depends on 18)

The method of therapeutically or prophylactically treating viral infection with coronaviridae in an individual according to claim 18, wherein the administration is by way of providing the individual with a pharmaceutical composition wherein the influenza virus defective particles are present in an amount sufficient to stimulate innate immunity against the virus in the individual.
